Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity

被引:5
|
作者
Flury, Philipp [1 ,2 ]
Breidenbach, Julian [3 ]
Krueger, Nadine [4 ]
Voget, Rabea [3 ]
Schaekel, Laura [3 ]
Si, Yaoyao [3 ]
Krasniqi, Vesa [3 ]
Calistri, Sara [1 ,2 ]
Olfert, Matthias [5 ]
Sylvester, Katharina [3 ]
Rocha, Cheila [4 ]
Ditzinger, Raphael [1 ,2 ]
Rasch, Alexander [1 ,2 ]
Poehlmann, Stefan [4 ,5 ]
Kronenberger, Thales [1 ,2 ,6 ,7 ]
Poso, Antti [1 ,2 ,6 ]
Rox, Katharina [8 ,9 ]
Laufer, Stefan A. [1 ,2 ]
Mueller, Christa E. [2 ,3 ]
Guetschow, Michael [3 ]
Pillaiyar, Thanigaimalai [1 ,2 ]
机构
[1] Eberhard Karls Univ Tubingen, Inst Pharm Pharmaceut Med Chem, D-72076 Tubingen, Germany
[2] Eberhard Karls Univ Tubingen, Tubingen Ctr Acad Drug Discovery, D-72076 Tubingen, Germany
[3] Univ Bonn, Pharmaceut Inst, PharmaCtr Bonn, Pharmaceut & Med Chem, D-53121 Bonn, Germany
[4] Leibniz Inst Primate Res, German Primate Ctr, Infect Biol Unit, D-37077 Gottingen, Germany
[5] Univ Goettingen, Fac Biol & Psychol, D-37073 Gottingen, Germany
[6] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland
[7] Excellence Cluster Controlling Microbes Fight Inf, D-72076 Tubingen, Germany
[8] Helmholtz Ctr Infect Res HZI, Dept Chem Biol, D-38124 Braunschweig, Germany
[9] German Ctr Infect Res DZIF, Partner Site Hannover Braunschweig, D-38124 Braunschweig, Germany
关键词
COVID-19; cathepsininhibitors; main protease; peptidomimetics; SARS-CoV-2; viral entry; MAIN PROTEASE; CYSTEINE; ENTRY; REACTIVITY; DISCOVERY;
D O I
10.1021/acsptsci.3c00313
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cathepsins (Cats) are proteases that mediate the successful entry of SARS-CoV-2 into host cells. We designed and synthesized a tailored series of 21 peptidomimetics and evaluated their inhibitory activity against human cathepsins L, B, and S. Structural diversity was realized by combinations of different C-terminal warhead functions and N-terminal capping groups, while a central Leu-Phe fragment was maintained. Several compounds were identified as promising cathepsin L and S inhibitors with K-i values in the low nanomolar to subnanomolar range, for example, the peptide aldehydes 9a and 9b (9a, 2.67 nM, CatL; 0.455 nM, CatS; 9b, 1.76 nM, CatL; 0.512 nM, CatS). The compounds' inhibitory activity against the main protease of SARS-CoV-2 (M-pro) was additionally investigated. Based on the results at CatL, CatS, and M-pro, selected inhibitors were subjected to investigations of their antiviral activity in cell-based assays. In particular, the peptide nitrile 11e exhibited promising antiviral activity with an EC50 value of 38.4 nM in Calu-3 cells without showing cytotoxicity. High metabolic stability and favorable pharmacokinetic properties make 11e suitable for further preclinical development.
引用
收藏
页码:493 / 514
页数:22
相关论文
共 50 条
  • [41] Virtual Screening and Molecular Design of Potential SARS-COV-2 Inhibitors
    O. V. Tinkov
    V. Yu. Grigorev
    L. D. Grigoreva
    Moscow University Chemistry Bulletin, 2021, 76 : 95 - 113
  • [42] Inhibitors of SARS-CoV-2 main protease: Biological efficacy and toxicity aspects
    Viskupicova, Jana
    Rezbarikova, Petronela
    Kovacikova, Lucia
    Kandarova, Helena
    Majekova, Magdalena
    TOXICOLOGY IN VITRO, 2023, 92
  • [43] Screening, Synthesis and Biochemical Characterization of SARS-CoV-2 Protease Inhibitors
    Bagdonas, Martynas
    Cerepenkaite, Kamile
    Mickeviciute, Aurelija
    Kananaviciute, Ruta
    Grybaite, Birute
    Anusevicius, Kazimieras
    Ruksenaite, Audrone
    Kojis, Tautvydas
    Gedgaudas, Marius
    Mickevicius, Vytautas
    Matulis, Daumantas
    Zubriene, Asta
    Matuliene, Jurgita
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [44] Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
    Breidenbach, Julian
    Lemke, Carina
    Pillaiyar, Thanigaimalai
    Schaekel, Laura
    Al Hamwi, Ghazl
    Diett, Miriam
    Gedschold, Robin
    Geiger, Nina
    Lopez, Vittoria
    Mirza, Salahuddin
    Namasivayam, Vigneshwaran
    Schiedel, Anke C.
    Sylvester, Katharina
    Thimm, Dominik
    Vielmuth, Christin
    Phuong Vu, Lan
    Zyulina, Maria
    Bodem, Jochen
    Guetschow, Michael
    Mueller, Christa E.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2021, 60 (18) : 10423 - 10429
  • [45] Asymmetric imidazole-4,5-dicarboxamide derivatives as SARS-CoV-2 main protease inhibitors: design, synthesis and biological evaluation
    Huynh, Phuong Nguyen Hoai
    Khamplong, Phatcharin
    Phan, Minh-Hoang
    Nguyen, Thanh-Phuc
    Vu, Phuong Ngoc Lan
    Tang, Quang-Vinh
    Chamsodsai, Phumin
    Seetaha, Supaphorn
    Tuong, Truong Lam
    Vu, Thien Y.
    Vo, Duc-Duy
    Choowongkomon, Kiattawee
    Vo, Cam-Van T.
    RSC MEDICINAL CHEMISTRY, 2024, 15 (11): : 3880 - 3888
  • [46] Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2
    Yan, Yong
    Liu, Hanwen
    Wu, Di
    Gu, Zhihao
    Guo, Wenhao
    Yao, Hequan
    Lin, Kejiang
    Li, Xuanyi
    FUTURE MEDICINAL CHEMISTRY, 2024, 16 (09) : 887 - 903
  • [47] Design, Synthesis, Biological Evaluation and Molecular Docking Studies of New Thiazolidinone Derivatives as NNRTIs and SARS-CoV-2 Main Protease Inhibitors
    Fesatidou, Maria
    Petrou, Anthi
    Geronikaki, Athina
    CHEMISTRY & BIODIVERSITY, 2024, 21 (12)
  • [48] SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System
    Min, Jung Sun
    Kwon, Sunoh
    Jin, Young-Hee
    BIOMEDICINES, 2021, 9 (08)
  • [49] Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions
    Liu, Xiaofeng
    Jiang, Luying
    Li, Li
    Lu, Fuping
    Liu, Fufeng
    HELIYON, 2023, 9 (01)
  • [50] Effect of farnesyltransferase inhibitors on SARS-CoV-2
    Weber, Lea
    Mautner, Lena
    Hoyos, Mona
    Ehrhardt, Anja
    Baiker, Armin
    Bachmann, Hagen Sjard
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2023, 32 : 164 - 166